
TY  - JOUR
TI  - PP-02 Risk Factors, Hormones and Epidemiology
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_14.x
DO  - doi:10.1111/j.1743-6109.2007.00390_14.x
SP  - 162
EP  - 174
PY  - 2007
ER  - 

TY  - JOUR
AU  - Vardi, Y.
AU  - Pedersen, C. Damsted
TI  - P-03 Female Sexual Health
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_3.x
DO  - doi:10.1111/j.1743-6109.2007.00390_3.x
SP  - 111
EP  - 114
PY  - 2007
ER  - 

TY  - JOUR
AU  - Marberger, M.
AU  - Briganti, A.
TI  - P-06 Erectile Dysfunction following Radical Prostatectomy
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_6.x
DO  - doi:10.1111/j.1743-6109.2007.00390_6.x
SP  - 121
EP  - 124
PY  - 2007
ER  - 

TY  - JOUR
AU  - Buvat, J.
AU  - Waldkirch, E.
TI  - P-01 Hormones and Sexuality
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_1.x
DO  - doi:10.1111/j.1743-6109.2007.00390_1.x
SP  - 105
EP  - 108
PY  - 2007
ER  - 

TY  - JOUR
AU  - Corona, G.
AU  - Simonsen, U.
TI  - MP-03 Physiology and Pathophysiology
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_10.x
DO  - doi:10.1111/j.1743-6109.2007.00390_10.x
SP  - 138
EP  - 143
PY  - 2007
ER  - 

TY  - JOUR
TI  - PP-01 Pharmacology
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_13.x
DO  - doi:10.1111/j.1743-6109.2007.00390_13.x
SP  - 152
EP  - 161
PY  - 2007
ER  - 

TY  - JOUR
TI  - PP-04 Ejaculatory Disorders
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_16.x
DO  - doi:10.1111/j.1743-6109.2007.00390_16.x
SP  - 183
EP  - 185
PY  - 2007
ER  - 

TY  - JOUR
AU  - Droupy, S.
AU  - Austoni, E.
TI  - P-07 Surgery and Peyronie's Disease
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_7.x
DO  - doi:10.1111/j.1743-6109.2007.00390_7.x
SP  - 124
EP  - 127
PY  - 2007
ER  - 

TY  - JOUR
AU  - Goldstein, I.
AU  - Richardson, D.
TI  - MP-01 Female Sexual Health
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_8.x
DO  - doi:10.1111/j.1743-6109.2007.00390_8.x
SP  - 128
EP  - 132
PY  - 2007
ER  - 

TY  - JOUR
AU  - Halfdanarson, Thorvardur R.
AU  - Walker, James A.
AU  - Litzow, Mark R.
AU  - Hanson, Curtis A.
TI  - Severe vitamin B12 deficiency resulting in pancytopenia, splenomegaly and leukoerythroblastosis
JO  - European Journal of Haematology
VL  - 80
IS  - 5
SN  - 0902-4441
UR  - https://doi.org/10.1111/j.1600-0609.2008.01043.x
DO  - doi:10.1111/j.1600-0609.2008.01043.x
SP  - 448
EP  - 451
KW  - B12 deficiency
KW  - pernicious anemia
KW  - pancytopenia
KW  - splenomegaly
KW  - leukoerythroblastosis
PY  - 2008
AB  - Abstract Deficiency of vitamin B12 is a well known cause of megaloblastic anemia and pancytopenia. Splenomegaly and leukoerythroblastosis are much less well known manifestations of B12 deficiency. We report a B12 deficient female with severe pancytopenia including normocytic anemia who also had enlarged spleen and circulating nucleated red blood cells as well as circulating immature myeloid cells. Although these findings are reported in the earlier literature, more modern reviews of the subject often fail to mention this association. We review the literature on these unusual manifestations of B12 deficiency and remind clinicians that splenomegaly and erythroblastosis can serve as diagnostic clues in cases of severe megaloblastic anemia secondary to B12 deficiency.
ER  - 

TY  - JOUR
TI  - PP-03 Female Sexual Function and Dysfunction
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_15.x
DO  - doi:10.1111/j.1743-6109.2007.00390_15.x
SP  - 175
EP  - 182
PY  - 2007
ER  - 

C7  - pp. 80-132
TI  - Skin and Soft Tissue Lesions
SN  - 9781444334340
UR  - https://doi.org/10.1002/9781118757017.ch2
DO  - doi:10.1002/9781118757017.ch2
SP  - 80-132
KW  - bone sarcomas
KW  - malignant melanoma
KW  - nonpigmented skin cancer
KW  - skin lesions
KW  - soft tissue tumours
PY  - 2007
AB  - Summary This chapter first presents some key notes on benign nonpigmented skin lesions and benign pigmented skin lesions. Nonpigmented skin cancer is the most common malignancy in the Western world: basal cell carcinoma (BCC); squamous cell carcinoma (SCC); merkel cell carcinoma (MCC); and sebaceous carcinoma. The chapter discusses malignant nonpigmented skin lesions in detail. It then explains malignant melanoma. A melanoma ? or malignant melanoma (MM) ? is a malignant tumour of melanocytes. Next, the chapter describes vascular anomalies that are generally managed by a multidisciplinary team (MDT) of specialists in supraregional centres. It then presents a brief discussion of soft tissue tumours and bone sarcomas.
ER  - 

TY  - JOUR
TI  - PP-06 General Issues in Sexual Medicine
JO  - The Journal of Sexual Medicine
VL  - 4
IS  - s2
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1743-6109.2007.00390_18.x
DO  - doi:10.1111/j.1743-6109.2007.00390_18.x
SP  - 195
EP  - 202
PY  - 2007
ER  - 

TY  - JOUR
AU  - Stincone, Anna
AU  - Prigione, Alessandro
AU  - Cramer, Thorsten
AU  - Wamelink, Mirjam M. C.
AU  - Campbell, Kate
AU  - Cheung, Eric
AU  - Olin-Sandoval, Viridiana
AU  - Grüning, Nana-Maria
AU  - Krüger, Antje
AU  - Tauqeer Alam, Mohammad
AU  - Keller, Markus A.
AU  - Breitenbach, Michael
AU  - Brindle, Kevin M.
AU  - Rabinowitz, Joshua D.
AU  - Ralser, Markus
TI  - The return of metabolism: biochemistry and physiology of the pentose phosphate pathway
JO  - Biological Reviews
JA  - Biol Rev
VL  - 90
IS  - 3
SN  - 9781444334340
UR  - https://doi.org/10.1111/brv.12140
DO  - doi:10.1111/brv.12140
SP  - 927
EP  - 963
KW  - pentose phosphate pathway
KW  - glycolysis
KW  - glucose 6-phosphate dehydrogenase
KW  - NADPH
KW  - metabolomics
KW  - oxidative stress
KW  - cancer
KW  - stem cells
KW  - host–pathogen interactions
KW  - metabolic engineering
KW  - inherited metabolic disease
KW  - parasitic protozoa
KW  - metabolism of infection
PY  - 2015
AB  - ABSTRACT The pentose phosphate pathway (PPP) is a fundamental component of cellular metabolism. The PPP is important to maintain carbon homoeostasis, to provide precursors for nucleotide and amino acid biosynthesis, to provide reducing molecules for anabolism, and to defeat oxidative stress. The PPP shares reactions with the Entner?Doudoroff pathway and Calvin cycle and divides into an oxidative and non-oxidative branch. The oxidative branch is highly active in most eukaryotes and converts glucose 6-phosphate into carbon dioxide, ribulose 5-phosphate and NADPH. The latter function is critical to maintain redox balance under stress situations, when cells proliferate rapidly, in ageing, and for the ?Warburg effect? of cancer cells. The non-oxidative branch instead is virtually ubiquitous, and metabolizes the glycolytic intermediates fructose 6-phosphate and glyceraldehyde 3-phosphate as well as sedoheptulose sugars, yielding ribose 5-phosphate for the synthesis of nucleic acids and sugar phosphate precursors for the synthesis of amino acids. Whereas the oxidative PPP is considered unidirectional, the non-oxidative branch can supply glycolysis with intermediates derived from ribose 5-phosphate and vice versa, depending on the biochemical demand. These functions require dynamic regulation of the PPP pathway that is achieved through hierarchical interactions between transcriptome, proteome and metabolome. Consequently, the biochemistry and regulation of this pathway, while still unresolved in many cases, are archetypal for the dynamics of the metabolic network of the cell. In this comprehensive article we review seminal work that led to the discovery and description of the pathway that date back now for 80 years, and address recent results about genetic and metabolic mechanisms that regulate its activity. These biochemical principles are discussed in the context of PPP deficiencies causing metabolic disease and the role of this pathway in biotechnology, bacterial and parasite infections, neurons, stem cell potency and cancer metabolism.
ER  - 

TY  - JOUR
TI  - Tuesday, 7 July 1998
JO  - British Journal of Haematology
VL  - 102
IS  - 1
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1365-2141.1998.tb08996.x
DO  - doi:10.1111/j.1365-2141.1998.tb08996.x
SP  - 140
EP  - 269
PY  - 1998
ER  - 

TY  - JOUR
TI  - REVIEW OF CURRENT LITERATURE
JO  - BJOG: An International Journal of Obstetrics & Gynaecology
VL  - 69
IS  - 1
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1471-0528.1962.tb00029.x
DO  - doi:10.1111/j.1471-0528.1962.tb00029.x
SP  - 161
EP  - 174
PY  - 1962
ER  - 

TY  - JOUR
AU  - Eyre, Toby A.
AU  - Clifford, Ruth
AU  - Bloor, Adrian
AU  - Boyle, Lucy
AU  - Roberts, Corran
AU  - Cabes, Maite
AU  - Collins, Graham P.
AU  - Devereux, Stephen
AU  - Follows, George
AU  - Fox, Christopher P.
AU  - Gribben, John
AU  - Hillmen, Peter
AU  - Hatton, Chris S.
AU  - Littlewood, Tim J.
AU  - McCarthy, Helen
AU  - Murray, Jim
AU  - Pettitt, Andrew R.
AU  - Soilleux, Elizabeth
AU  - Stamatopoulos, Basile
AU  - Love, Sharon B.
AU  - Wotherspoon, Andrew
AU  - Schuh, Anna
TI  - NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 175
IS  - 1
SN  - 9781444334340
UR  - https://doi.org/10.1111/bjh.14177
DO  - doi:10.1111/bjh.14177
SP  - 43
EP  - 54
KW  - Ofatumumab
KW  - CHOP
KW  - TP53
KW  - Richter syndrome
KW  - Chronic lymphocytic leukaemia
PY  - 2016
AB  - Richter syndrome (RS) is associated with chemotherapy resistance and a poor historical median overall survival (OS) of 8?10 months. We conducted a phase II trial of standard CHOP-21 (cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 d) with ofatumumab induction (Cycle 1: 300 mg day 1, 1000 mg day 8, 1000 mg day 15; Cycles 2?6: 1000 mg day 1) (CHOP-O) followed by 12 months ofatumumab maintenance (1000 mg given 8-weekly for up to six cycles). Forty-three patients were recruited of whom 37 were evaluable. Seventy-three per cent were aged >60 years. Over half of the patients received a fludarabine and cyclophosphamide-based regimen as prior CLL treatment. The overall response rate was 46% (complete response 27%, partial response 19%) at six cycles. The median progression-free survival was 6·2 months (95% confidence interval [CI] 4·9?14·0 months) and median OS was 11·4 months (95% CI 6·4?25·6 months). Treatment-naïve and TP53-intact patients had improved outcomes. Fifteen episodes of neutropenic fever and 46 non-neutropenic infections were observed. There were no treatment-related deaths. Seven patients received platinum-containing salvage at progression, with only one patient obtaining an adequate response to proceed to allogeneic transplantation. CHOP-O with ofatumumab maintenance provides minimal benefit beyond CHOP plus rutuximab. Standard immunochemotherapy for RS remains wholly inadequate for unselected RS. Multinational trials incorporating novel agents are urgently needed.
ER  - 

TY  - JOUR
TI  - Oral Sessions
JO  - Transplant International
VL  - 24
IS  - s2
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1432-2277.2011.01346.x
DO  - doi:10.1111/j.1432-2277.2011.01346.x
SP  - 1
EP  - 95
PY  - 2011
ER  - 

TY  - JOUR
TI  - Motility/Neurogastroenterology
JO  - Journal of Gastroenterology and Hepatology
VL  - 27
IS  - s4
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1440-1746.2011.07251_10.x
DO  - doi:10.1111/j.1440-1746.2011.07251_10.x
SP  - 150
EP  - 157
PY  - 2012
ER  - 

TY  - JOUR
TI  - Basic Science Luminal
JO  - Journal of Gastroenterology and Hepatology
VL  - 27
IS  - s4
SN  - 9781444334340
UR  - https://doi.org/10.1111/j.1440-1746.2011.07251_2.x
DO  - doi:10.1111/j.1440-1746.2011.07251_2.x
SP  - 17
EP  - 29
PY  - 2012
ER  - 
